Browse the evidence

Aging is associated with a decline in gut microbiota diversity, a decrease in beneficial butyrate-producing bacteria, and an increase in opportunistic pathogens, correlating with increased frailty and inflammation.

As you age, your gut bacteria change, often becoming less diverse and producing fewer beneficial compounds. This is linked to frailty. Maintaining a high-fiber diet and social engagement (if in care) may help preserve microbiota diversity.

Dapagliflozin monotherapy reduces hepatocyte injury biomarkers and FGF21 levels, suggesting a disease-modifying effect on NAFLD/NASH, but this effect is negated when combined with OM-3CA.

Dapagliflozin alone (10 mg daily) significantly reduces markers of liver cell injury (such as AST, ALT, and GGT) and FGF21 in patients with Type 2 Diabetes and NAFLD, suggesting it may modify the disease. However, adding OM-3CA (4 g daily) negates this specific benefit on injury biomarkers, even though the combination is superior for reducing total liver fat.

Melatonin acts as a mitochondria-targeted antioxidant by accumulating in high concentrations within mitochondria via oligopeptide transporters (PEPT1/2), where it directly scavenges reactive oxygen species (ROS) and stimulates antioxidant enzymes (SOD, GPx) to mitigate oxidative stress and age-related decline.

Melatonin is not just a sleep hormone; it is a potent antioxidant that concentrates inside your cells' energy producers (mitochondria). This positioning allows it to neutralize damaging free radicals more effectively than many other antioxidants, potentially slowing age-related cellular decline. While the paper focuses on mechanisms, this suggests that maintaining healthy melatonin rhythms or supplementation could support long-term cellular health.

Microalgae species with robust cell walls (e.g., Porphyridium, Phaeodactylum) exhibit significantly lower in vitro digestibility compared to species with simpler cell structures (e.g., Arthrospira, Chlorella vulgaris), limiting nutrient bioavailability.

If you are choosing a microalgae supplement, look for species known for high digestibility like Arthrospira (Spirulina) or Chlorella vulgaris. Species like Porphyridium or Phaeodactylum may have lower nutrient absorption due to tough cell walls. Processing methods (like breaking cell walls) can mitigate this, but raw biomass digestibility varies significantly by strain.

Aging is characterized by a specific redistribution of body composition involving increased total fat mass and visceral adiposity alongside decreased lean mass and bone density, which drives chronic low-grade inflammation (metaflammation) and increases the risk of age-related diseases independent of overall body weight or BMI.

As you age, your weight might stay the same, but your body composition changes: you gain fat (especially around the organs) and lose muscle and bone. This 'silent' change is more dangerous than being overweight. Do not rely on BMI. Focus on maintaining muscle mass through strength training and protein intake, and monitor visceral fat via imaging if possible, as this specific type of fat drives inflammation and disease risk.

MRI is the most advanced and accurate technique for evaluating muscle quality and detecting early fatty infiltration (sarcopenia) in aging, offering superior contrast between fat and muscle compared to CT or DXA, despite higher costs and complexity.

For the most detailed look at muscle health, especially to detect early muscle loss (sarcopenia) before it becomes obvious, MRI is the best tool. It can see fat inside muscles that other scans miss. However, due to cost and availability, it is typically reserved for research or complex cases rather than routine check-ups.

Randomized controlled trials (RCTs) of nonnutritive sweeteners show no consistent effect on BMI, weight, or waist circumference over short-to-medium term follow-up (median 6 months).

Don't expect nonnutritive sweeteners to cause weight loss. Short-term controlled trials show no significant effect on BMI or weight. They can be part of a calorie-reduced diet, but they don't drive weight loss themselves.

Palmitate (a saturated free fatty acid) induces oxidative stress and endoplasmic reticulum (ER) calcium depletion, triggering a vicious cycle of mitochondrial dysfunction and apoptosis that leads to pancreatic beta-cell failure and insulin resistance.

High levels of saturated fats (specifically palmitate) in the blood can overwhelm cellular machinery, causing stress that damages insulin-producing cells and reduces insulin sensitivity. This risk is heightened in people with existing insulin resistance. However, not all fats behave this way; unsaturated fats (like oleate) can mitigate this damage. Managing saturated fat intake and maintaining a healthy weight to lower circulating free fatty acids are key strategies to prevent this cellular stress cycle.

The kynurenine/tryptophan (Kyn/Trp) ratio in blood serves as a robust biomarker for the rate of physiological aging (inflammaging) and predicts age-related diseases and mortality.

You can monitor your Kyn/Trp ratio as a blood test to assess your biological aging rate and risk for age-related diseases. A higher ratio indicates increased inflammatory activity associated with aging. This is a diagnostic tool, not a treatment, but it helps identify who might benefit from lifestyle interventions targeting inflammation.

Mitochondrial dysfunction, including impaired beta-oxidation and increased ROS production, is a major contributing factor to NAFLD progression.

Healthy mitochondria are crucial for liver health. Exercise and weight loss help improve mitochondrial function, which may reduce liver damage.

The effect of maternal hyperglycemia on childhood adiposity (overweight/obesity and sum of skinfold thickness) is sex-specific, being significant in girls but not in boys.

For girls exposed to maternal hyperglycemia in utero, parents should be particularly vigilant about monitoring weight and body composition, as they are at higher risk for childhood obesity and adiposity compared to boys. Regular check-ups focusing on growth charts and body fat percentage are recommended for these girls.

Obesity and overweight are associated with a gut microbiota profile characterized by a significantly higher Firmicutes-to-Bacteroidetes ratio, increased abundance of SCFA-producing Firmicutes taxa (e.g., Lachnospiraceae, Ruminococcus gnavus), and decreased abundance of Bacteroidetes taxa (e.g., Bacteroides uniformis, Flavobacteriaceae).

Your gut bacteria composition changes with obesity, specifically showing more Firmicutes and fewer Bacteroidetes. This isn't just a side effect; these bacteria influence how you harvest energy and store fat. To shift your microbiome toward a healthier profile, focus on increasing dietary fiber intake and physical activity, which are associated with higher Bacteroidetes abundance and lower Firmicutes dominance.

Increased abundance of specific Firmicutes taxa (e.g., Ruminococcus gnavus, Lachnospiraceae) and Proteobacteria (e.g., Escherichia, Enterobacteriaceae) in obesity contributes to chronic low-grade inflammation and metabolic endotoxemia via LPS production and mucin degradation.

Obesity is linked to an increase in bacteria that produce lipopolysaccharides (LPS), which can leak into the bloodstream and cause chronic inflammation. This inflammation is fueled by a diet low in fiber and high in saturated fats. Prioritize fiber-rich foods (vegetables, legumes, whole grains) to support bacteria that maintain gut barrier integrity and reduce inflammation.

The increased risk of IGT and T2DM in PCOS is significantly modified by ethnicity, with Asian and American populations showing higher odds ratios than European populations, and this risk persists even when BMI is matched.

Your ethnicity matters for your diabetes risk with PCOS. Asian and Hispanic/Latina women with PCOS face a higher risk than white women, even if they are the same weight. This means you may need more aggressive screening or lifestyle interventions regardless of your BMI.

PPARα activation via fibrates improves lipid profiles (lowering triglycerides and raising HDL-C) but does not improve glucose homeostasis in patients with type 2 diabetes.

If you have type 2 diabetes and high triglycerides/low HDL, fibrates (PPARα agonists) can help your lipid profile and reduce cardiovascular risk, but they will not lower your blood sugar. You likely still need a medication that targets glucose (like a PPARγ agonist) for diabetes management.

PPARγ activation via thiazolidinediones (TZDs) improves glycemic control and insulin sensitivity but causes adverse effects including weight gain, edema, and increased fracture risk.

PPARγ drugs (TZDs) are very effective at lowering blood sugar and improving insulin sensitivity. However, they can cause weight gain, swelling (edema), and increase the risk of bone fractures. Discuss these risks with your doctor, especially if you have osteoporosis.

YouTube is not a reliable source of medical and health-related information, as aggregated evidence shows content quality is average to below-average and popularity metrics (views/likes) do not correlate with quality.

Do not use YouTube as your primary source for medical decisions. The platform's algorithm promotes popular content, which is often low-quality or misleading. If you must use YouTube, look for videos from verified, reputable institutions (e.g., major hospitals, professional societies) and cross-reference the information with a healthcare provider. Be skeptical of videos with high view counts but low medical detail.

Females experience greater central limitations to whole-body exercise performance due to smaller lung volumes and airways, leading to higher mechanical work of breathing and a greater prevalence of exercise-induced arterial hypoxemia (EIAH).

Women may experience breathing-related fatigue sooner than men during high-intensity whole-body exercise due to smaller airways and lungs. This can limit performance despite good muscle endurance. Training that improves respiratory efficiency or pacing strategies may be beneficial.

Glycine deficiency in metabolic disorders is driven by three simultaneous mechanisms: decreased gut absorption, decreased endogenous biosynthesis, and increased catabolism or urinary excretion.

Low glycine in metabolic disease isn't just about what you eat; it's about how your body processes it. Your gut bacteria may be consuming it, your liver may be making less of it, and your kidneys may be excreting it faster. Addressing this requires a holistic approach to metabolic health rather than just supplementation.

Obesity prevalence trends in high-income countries have stabilized or plateaued since approximately 2000, contrasting with continuous increases in low- and middle-income nations.

If you live in a high-income country, the trend of rising obesity rates has likely slowed or stopped for your demographic since 2000. This suggests that societal changes (diet, activity) have reached a new equilibrium. However, this stability is not guaranteed to persist, and severe obesity is still rising, so individual action remains critical.

Severe obesity is rising rapidly in high-income countries and is projected to double in prevalence between 2020 and 2035, posing a significant threat to healthcare systems.

Even if general obesity rates have stabilized in your country, severe obesity is doubling. This means the health risks and healthcare costs are increasing significantly. Focus on preventing the progression to severe obesity through early intervention.

PGC-1α regulates mitochondrial quality control mechanisms, including fission, fusion, and mitophagy, which impacts age-related mitochondrial dysfunction and insulin sensitivity.

Focus on exercises that stimulate PGC-1α, such as endurance training, to support mitochondrial quality control, not just volume. This may help maintain metabolic health and insulin sensitivity as you age.

PGC-1α plays an important role in skeletal muscle ROS balance through the regulation of anti-oxidant proteins and proton leak.

Exercise that boosts PGC-1α may help manage oxidative stress by enhancing anti-oxidant defenses and reducing proton leak.

Fasting sweat glucose levels do not robustly predict fasting blood glucose levels across a population of healthy and diabetic subjects, limiting the use of sweat glucose for universal diabetes diagnostics.

Do not rely on sweat glucose sensors to make immediate medical decisions about insulin dosing or hypoglycemia treatment based on population averages. The correlation between sweat and blood glucose is too weak and variable across individuals. Current technology may support personalized longitudinal tracking, but it is not yet a universal diagnostic tool.